Awardee OrganizationCASE WESTERN RESERVE UNIVERSITY
Description
Abstract Text
Abstract
Infectious bacteria and inflammatory insults can be so toxic to an organism that they require an immediate
response. One such response, called pyroptosis, causes an inflammatory cell death that both alerts the
immune system to the immediate threat and also ensures a continued inflammatory effort. In classical
pyroptosis, Caspase-1 or Caspase-11 (Caspase-4/5 human) cleaves the pore forming protein, Gasdermin D
(GSDMD). This cleaved GSDMD then oligomerizes to form a pore in cellular membranes. Gasdermin D pore
formation allows the acute release of IL-1 from the cell, while also destroying membrane integrity such that
mitochondrial damage and electrolyte imbalances quickly kill the cell. Implicit in this is that should pyroptosis
be blocked, either genetically or pharmacologically, neutralization of the pathogen is so important to
organismal survival that alternative mechanisms to initiate cytokine release and inflammatory cell death must
have evolved. We are only now beginning to understand these compensatory responses and their role in
shaping the immune response. Our preliminary data, with support from the preliminary data from the other
three projects in this PPG application, will establish that mechanisms of compensation involve both Gasdermin
redundancy and alternative protease cleavage events. We hypothesize that these compensatory mechanisms
are cell-type specific. We further posit that they influence the timing and amplitude of cytokine release, the
timing and inflammatory capacity of the resulting cell death and the in vivo immune response to inflammatory
stimuli. The overall hypothesis of this application is that mechanisms to compensate for loss of pyroptosis
alter the inflammatory and immunologic response to an inflammatory insult. We further hypothesize that this
compensation helps establish myeloid cell homeostasis and that disruption of these compensatory
mechanisms influences the pathologic development of Myelodysplasia and subsequent Leukemia progression.
The long-term goal of this work is to better understand how pyroptotic compensatory mechanisms influence
the inflammatory response and immunologic homeostasis in hopes of better understanding how to manipulate
these pathways in disease.
Public Health Relevance Statement
Lay Summary
Throughout human history, infectious diseases and inflammatory such as the flu or cold viruses or stomach
bugs, have been drivers of human evolution. These threats are so dangerous that humans have evolved
redundant mechanisms to neutralize them. The Gasdermin family of proteins helps drive inflammation in the
face of these threats. Despite this, little is known about Gasdermin family redundancy, the mechanisms by
which Gasdermin family members are regulated and Gasdermin family members role in normal blood cell
development. This grant application aims to study these important problems in the context of inflammatory
disease.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
077758407
UEI
HJMKEF7EJW69
Project Start Date
24-July-2020
Project End Date
30-June-2025
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$427,816
Direct Costs
$265,724
Indirect Costs
$162,092
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$427,816
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI141350-05 6244
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI141350-05 6244
Patents
No Patents information available for 5P01AI141350-05 6244
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI141350-05 6244
Clinical Studies
No Clinical Studies information available for 5P01AI141350-05 6244
News and More
Related News Releases
No news release information available for 5P01AI141350-05 6244
History
No Historical information available for 5P01AI141350-05 6244
Similar Projects
No Similar Projects information available for 5P01AI141350-05 6244